(S)-3-{(S)-1-[Hydroxy-((R)-1-phenyl-ethylcarbamoyl)-methyl]-pentylcarbamoyloxy}-4,4-dimethyl-2-oxo-pyrrolidine-1-carboxylic acid benzyl ester | 907564-04-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-3-{(S)-1-[Hydroxy-((R)-1-phenyl-ethylcarbamoyl)-methyl]-pentylcarbamoyloxy}-4,4-dimethyl-2-oxo-pyrrolidine-1-carboxylic acid benzyl ester
• CAS: 907564-04-9
• 化学式: C₃₀H₃₉N₃O₇
• 分子量: 553.656
• InChiKey: CCEWQYPGWPWDJV-LVZIWVBMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.08
• 重原子数：
  40.0
• 可旋转键数：
  11.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  134.27
• 氢给体数：
  3.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  (S)-3-{(S)-1-[Hydroxy-((R)-1-phenyl-ethylcarbamoyl)-methyl]-pentylcarbamoyloxy}-4,4-dimethyl-2-oxo-pyrrolidine-1-carboxylic acid benzyl ester 在 palladium on activated charcoal 草酰氯 、 氢气 、 二甲基亚砜 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 [(S)-1-((R)-1-Phenyl-ethylaminooxalyl)-pentyl]-carbamic acid (S)-4,4-dimethyl-2-oxo-pyrrolidin-3-yl ester
  参考文献：
  名称：

  A structural screening approach to ketoamide-based inhibitors of cathepsin K

  摘要：

  Several novel ketoamide-based inhibitors of cathepsin K have been identified. Starting from a modestly potent inhibitor, structural screening of P-2 elements led to 100-fold enhancements in inhibitory activity. Modifications to one of these leads resulted in an orally bioavailable cathepsin K inhibitor. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.023
• 作为产物：
  描述：

  (S)-3-Hydroxy-4,4-dimethyl-pyrrolidin-2-one 在 吡啶 、 4-二甲氨基吡啶 、 四丁基氟化铵 、 sodium hydride 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 甲苯 为溶剂， 生成 (S)-3-{(S)-1-[Hydroxy-((R)-1-phenyl-ethylcarbamoyl)-methyl]-pentylcarbamoyloxy}-4,4-dimethyl-2-oxo-pyrrolidine-1-carboxylic acid benzyl ester
  参考文献：
  名称：

  A structural screening approach to ketoamide-based inhibitors of cathepsin K

  摘要：

  Several novel ketoamide-based inhibitors of cathepsin K have been identified. Starting from a modestly potent inhibitor, structural screening of P-2 elements led to 100-fold enhancements in inhibitory activity. Modifications to one of these leads resulted in an orally bioavailable cathepsin K inhibitor. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.023